Compare Merck & Co., Inc. (MRK) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Sirius XM Holdings Inc — how do they compare? Merck & Co., Inc. trades at $148.18 (market cap $366.28B), while Sirius XM Holdings Inc trades at $28.71 (market cap $9.71B). The key difference: Merck & Co., Inc. is far larger — about 37.7× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| MRK | SIRI | |
|---|---|---|
Market Cap | $366.28B | $9.71B |
Sector | Health | Media |
52-Week High | $156.43 | $32.59 |
52-Week Low | $77.60 | $19.92 |
Enterprise Value | $413.04B | $18.99B |
Dividend Yield | 2.29% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Sirius XM Holdings Inc. (SIRI) trades at $28.80, down 0.66% today, with a bullish technical signal from moving averages and a consensus analyst price target of $34.86. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Financials show a net income margin of 10.23% for 2025, with revenue at $8.56B, while the balance sheet indicates a debt-to-asset ratio improvement to 35.63% in 2025. Recent news highlights a YouTube partnership expected to boost EBITDA by 2029.
The outlook for SIRI is positive, supported by analyst upgrades and institutional buying, but risks include competitive pressures in audio streaming and reliance on advertising growth. The stock's valuation metrics, such as a P/E of 11.57 and P/B of 0.82, suggest potential upside if earnings improve, though volatility from market sentiment remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
